HDAC inhibitor such as approved by the FDA to treat non-refractory MM, panobinostat (LBH589), reduces cell growth and induces apoptosis in MM cells as a single agent, however, synergistic activity has been also observed in combination with bortezomib (Hideshima, Richardson, and Anderson, 2011). The gene discussed is HDAC9; the disease is Miyoshi myopathy.